Summit Therapeutics Inc (SMMT) concluded trading on Wednesday at a closing price of $28.27, with 6.14 million shares of worth about $173.48 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 55.54% during that period and on July 16, 2025 the price saw a gain of about 16.05%. Currently the company’s common shares owned by public are about 741.61M shares, out of which, 111.44M shares are available for trading.
Stock saw a price change of 14.27% in past 5 days and over the past one month there was a price change of 42.92%. Year-to-date (YTD), SMMT shares are showing a performance of 230.64% which increased to 58.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.71 but also hit the highest price of $36.91 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 4.87 million. The stock is currently trading 24.55% above its 20-day simple moving average (SMA20), while that difference is up 23.82% for SMA50 and it goes to 34.90% higher than SMA200.
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 741.61M outstanding shares and institutions hold larger chunk of about 13.21% of that.
The stock has a current market capitalization of $21.00B and its 3Y-monthly beta is at -1.07. It has posted earnings per share of -$0.33 in the same period. It has Quick Ratio of 10.63 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 7.38% while standing at 6.83% over the month.
Stock’s fiscal year EPS is expected to drop by -28.39% while it is estimated to decrease by -30.83% in next year. EPS is likely to shrink at an annualized rate of -21.52% for next 5-years, compared to annual growth of -10.52% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on July 01, 2025 offering a Buy rating for the stock and assigned a target price of $30 to it. Coverage by Leerink Partners stated Summit Therapeutics Inc (SMMT) stock as an Underperform in their note to investors on June 11, 2025, suggesting a price target of $12 for the stock. Stock get an Outperform rating from Evercore ISI on March 12, 2025.
